Compare Hims and Hers Health Inc (HIMS) vs Nutanix Inc (NTNX) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Nutanix (NTNX) trades at $55.11, showing minimal daily change. The stock exhibits a bullish technical trend, supported by strong earnings beats in recent quarters, including Q1 2026 EPS of $0.47 versus $0.36 expected. Revenue growth is projected to increase from $2.54 billion in 2025 to $2.7 billion in 2026, with net income margin improving to 10.03%. Positive sentiment is fueled by recent news, such as the NVIDIA certification for its Unified Storage solution, highlighting its position in AI infrastructure.

The outlook for NTNX is positive, driven by consistent earnings outperformance and strategic positioning in hybrid multicloud and AI markets. Key opportunities include expanding profit margins and leveraging partnerships. Risks involve competitive pressures in cloud computing and reliance on enterprise spending. The consensus analyst price target of $57.80 suggests moderate upside from current levels.